[Skip to Content]
[Skip to Content Landing]
December 1956

Effect of Acetazoleamide on the Dark-Adaptation Function in Glaucoma

Author Affiliations

New York
From the Department of Ophthalmology of the New York University Post-Graduate Medical School.

AMA Arch Ophthalmol. 1956;56(6):869-877. doi:10.1001/archopht.1956.00930040881010

It is well recognized that the light sense suffers in cases of chronic glaucoma.12 Investigators as long as 30 years ago showed that the light minimum was considerably raised and the dark-adaptation rate retarded in cases of simple glaucoma.11

The carbonic anhydrase inhibitor acetazoleamide (Diamox) has recently found widespread acceptance among ophthalmologists as a new antiglaucoma agent. The purpose of this study is to determine whether the use of acetazoleamide has a detrimental effect on the dark-adapting function of the eye suffering from glaucoma.

Method and Material  The experiment consisted of periodically determining dark-adaptation curves of six glaucoma patients, all of whom were using pilocarpine therapeutically. Once a satisfactory "base line" curve was obtained, acetazoleamide administration was begun and was continued for varying periods of time and with varying dosages. The accompanying graphs are self-explanatory. It should be pointed out, however, that the points plotted under 0 weeks